1
|
Mandili G, Follia L, Ferrero G, Katayama H, Hong W, Momin AA, Capello M, Giordano D, Spadi R, Satolli MA, Evangelista A, Hanash SM, Cordero F, Novelli F. Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. Cancers (Basel) 2020; 12:E746. [PMID: 32245227 PMCID: PMC7140049 DOI: 10.3390/cancers12030746] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 03/14/2020] [Accepted: 03/18/2020] [Indexed: 12/12/2022] Open
Abstract
Pancreatic Ductal Adenocarcinoma (PDA) is an aggressive malignancy with a very poor outcome. Although chemotherapy (CT) treatment has poor efficacy, it can enhance tumor immunogenicity. Tumor-Associated Antigens (TAA) are self-proteins that are overexpressed in tumors that may induce antibody production and can be PDA theranostic targets. However, the prognostic value of TAA-antibody association as Circulating Immune Complexes (CIC) has not yet been elucidated, mainly due to the lack of techniques that lead to their identification. In this study, we show a novel method to separate IgG, IgM, and IgA CIC from sera to use them as prognostic biomarkers of CT response. The PDA Immune-Complexome (IC) was identified using a LTQ-Orbitrap mass spectrometer followed by computational analysis. The analysis of the IC of 37 PDA patients before and after CT revealed differential associated antigens (DAA) for each immunoglobulin class. Our method identified different PDA-specific CIC in patients that were associated with poor prognosis patients. Finally, CIC levels were significantly modified by CT suggesting that they can be used as effective prognostic biomarkers to follow CT response in PDA patients.
Collapse
Affiliation(s)
- Giorgia Mandili
- Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Torino, Italy; (G.M.); (L.F.)
- Center for Experimental Research and Medical Studies (CeRMS), University of Turin, 10126 Torino, Italy
| | - Laura Follia
- Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Torino, Italy; (G.M.); (L.F.)
- Center for Experimental Research and Medical Studies (CeRMS), University of Turin, 10126 Torino, Italy
- Department of Computer Science, University of Turin, 10149 Torino, Italy; (G.F.); (F.C.)
| | - Giulio Ferrero
- Department of Computer Science, University of Turin, 10149 Torino, Italy; (G.F.); (F.C.)
- Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, 10043 Orbassano, Turin, Italy
| | - Hiroyuki Katayama
- MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
| | - Wang Hong
- MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
| | - Amin A. Momin
- MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
| | - Michela Capello
- MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
| | - Daniele Giordano
- Center for Experimental Research and Medical Studies (CeRMS), University of Turin, 10126 Torino, Italy
| | - Rosella Spadi
- Centro Oncologico Ematologico Subalpino (COES), University of Turin, 10126 Torino, Italy
| | | | - Andrea Evangelista
- Cittá della salute e della scienza University Hospital of Turin, University of Turin, 10126 Torino, Italy
| | - Samir M. Hanash
- MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
| | - Francesca Cordero
- Department of Computer Science, University of Turin, 10149 Torino, Italy; (G.F.); (F.C.)
| | - Francesco Novelli
- Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Torino, Italy; (G.M.); (L.F.)
- Center for Experimental Research and Medical Studies (CeRMS), University of Turin, 10126 Torino, Italy
- Cittá della salute e della scienza University Hospital of Turin, University of Turin, 10126 Torino, Italy
| |
Collapse
|